Clinical trials: Multiple Chronic Diseases
Chronic Pain, Brain Injuries, Traumatic
Telehealth Pain Self-Management for Employed Adults
The E-TIPS trial will evaluate an evidence-based, telehealth pain self-management intervention compared to standard care (a waitlist) for chronic pain in adults with physical disabilities who are employed.
- Conditions
- Chronic Pain, Brain Injuries, Traumatic, Multiple Sclerosis, Spinal Cord Injuries
- Trial name
- E-TIPS (NCT04248725)
- Testing
- E-TIPS
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- University of Washington
Cerebral Palsy, Multiple Sclerosis
Measuring Signatures in the Fluid Surrounding the Spinal Cord in Patients Who Have Problems With Intrathecal Drug Delivery
The purpose of this study is to record signatures from the fluid surrounding the spinal cord from people who have an implanted drug infusion system.
- Conditions
- Cerebral Palsy, Multiple Sclerosis, Traumatic Brain Injury, Spinal Cord Injury
- Trial name
- NCT01117090
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- MedtronicNeuro
Lymphoma, Multiple Myeloma
Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY
The purpose of this research is to find the most effective and least toxic way to prevent GVHD after BMT.
- Conditions
- Lymphoma, Multiple Myeloma, Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT00809276
- Testing
- Busulfan, Fludarabine, Cytoxan
- Where
- 3 sites in United States
- Volunteers
- 92 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hepatitis B, Chronic
A Study of Switching From Entecavir to Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B
Tenofovir Disoproxil Fumarate is a nucleos(t)ide analogue that inhibits Hepatitis B Virus (HBV) growth, and is marketed in Japan with an indication for inhibition of HBV growth in subjects with chronic hepatitis B associated with…
- Trial name
- NCT03258710
- Testing
- Tenofovir Disoproxil Fumarate
- Where
- 18 sites in Japan
- Volunteers
- 75 people
- Sponsor
- GlaxoSmithKline
Purpura, Thrombocytopenic, Idiopathic
Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).
BI 655064 will be administered subcutaneously once weekly in patients with immune thrombocytopenic purpura (ITP) for up to 12 weeks.
- Trial name
- NCT02009761
- Testing
- BI 655064
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
PT003 MDI Cardiovascular Safety Study
This study is primarily a safety study. The primary and secondary endpoints are based on 24-hour Holter monitor assessments obtained on Day 14 relative to baseline.
- Trial name
- NCT01349803
- Testing
- PT005 MDI, PT001 MDI, PT003 MDI
- Where
- 20 sites in United States, Australia and 1 more
- Volunteers
- 237 people
- Sponsor
- Pearl Therapeutics, Inc.
Alpha 1-Antitrypsin Deficiency
Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults
The purpose of this clinical study (ChAMP - Comparability pharmacokinetics of Alpha-1 Modified Process) is to compare the pharmacokinetic, safety and tolerability of Alpha-1 Proteinase Inhibitor (Human), modified process (Alpha-1…
- Trial name
- ChAMP (NCT00295061)
- Testing
- Alpha-1 MP, alpha-1 proteinase inhibitor (human)
- Where
- 8 sites in United States
- Volunteers
- 24 people
- Sponsor
- Grifols Therapeutics LLC
Chronic Obstructive Pulmonary Disease
Long Term Safety and Tolerability of NVA237 Versus Tiotropium in Japanese Patients
This is a 52-week, multi-center, randomized, open label, parallel group study to assess the long term safety and tolerability of once-daily NVA237, using tiotropium as an active control, in Japanese patients with moderate to…
- Trial name
- GLOW4 (NCT01119937)
- Testing
- NVA237, Tiotropium
- Where
- 40 sites in Japan
- Volunteers
- 211 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
Direct comparison studies of the tiotropium HandiHaler® 18 µg and Respimat® 5 µg formulations have been limited to 4-week crossover studies.
- Trial name
- NCT01126437
- Testing
- tiotropium 18 mcg, tiotropium 1.25 mcg (2 actuations/day), tiotropium 2.5 mcg (2 actuations/day)
- Where
- 1,191 sites in United States, Argentina and 49 more
- Volunteers
- 17,183 people
- Sponsor
- Boehringer Ingelheim
Diabetic Foot Ulcer
The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients (A6301086)
The primary objective of this 6 month open-label extension trial is to evaluate long-term safety and tolerability of dalteparin in treatment of chronic neuroischaemic foot ulcers in diabetic patients with peripheral arterial…
- Trial name
- NCT00765063
- Testing
- Fragmin
- Where
- 27 sites in Austria, Belgium and 12 more
- Volunteers
- 62 people
- Sponsor
- Pfizer
Leukemia, Lymphoma
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00719849
- Testing
- anti-thymocyte globulin, cyclophosphamide, cyclosporine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Fred Hutchinson Cancer Center
Anemia, Chronic Kidney Disease
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
The primary objectives of this study are the following: 1. To test if the proportion of participants achieving a hemoglobin value greater than or equal to 10.0 g/dL at any time point after the first dose during the study is…
- Conditions
- Anemia, Chronic Kidney Disease, Kidney Disease
- Trial name
- NCT00436748
- Testing
- Darbepoetin Alfa
- Where
- 67 sites in United States, Belgium and 8 more
- Volunteers
- 116 people
- Sponsor
- Amgen
Graft Versus Host Disease, Leukemia
Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil
RATIONALE: Giving chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's…
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00608517
- Testing
- anti-thymocyte globulin, cyclophosphamide, fludarabine phosphate
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Pulmonary Hypertension
BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension
Patients who have completed the 16 weeks treatment of the CHEST-1 trial (study number 11348) will be asked to participate in this long term extension study with BAY63-2521.
- Trial name
- CHEST-2 (NCT00910429)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 73 sites in United States, Argentina and 24 more
- Volunteers
- 237 people
- Sponsor
- Bayer
Diabetic Foot Ulcer
Study Of The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients
The purpose of the study isto see the effect of Fragmin on the healing of diabetic foot ulcers by determining the number of subjects with ≥50% reduction in ulcer surface area including intact skin healing.
- Trial name
- FEENICS (NCT00662831)
- Testing
- Fragmin/ Dalteparin Sodium
- Where
- 63 sites in Austria, Belgium and 15 more
- Volunteers
- 276 people
- Sponsor
- Pfizer
B-cell Follicular Lymphoma, B-cell Marginal Zone Lymphoma
Study of MLN8237 in Participants With Advanced Hematological Malignancies
This is an open-label, multicenter, phase 1 study of MLN8237 in participants with advanced hematological malignancies for whom there are limited standard treatment options.
- Conditions
- B-cell Follicular Lymphoma, B-cell Marginal Zone Lymphoma, Diffuse Large B-cell Lymphoma, B-cell Mantle Cell Lymphoma
- Trial name
- NCT00697346
- Testing
- Alisertib
- Where
- 10 sites in United States
- Volunteers
- 58 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Psoriasis
A Dose Ranging Study to Evaluate the Safety and Efficacy of GSK2586184 in Patients With Chronic Plaque Psoriasis
A multi-centre, randomised, dose ranging study to evaluate the safety and clinical efficacy of GSK2586184 in patients with chronic plaque psoriasis. There will be 2 study cohorts (Cohorts A and B).
- Trial name
- NCT01782664
- Testing
- 100 mg GSK2586184, 200 mg GSK2586184, 400 mg GSK2586184
- Where
- 15 sites in Germany, United Kingdom
- Volunteers
- 68 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.
The purpose of this study is to demonstrate that the efficacy of the combination product QVA149 is similar to the efficacy of the combination product umeclidinium/vilanterol on a pre-specified endpoint of FEV1 AUC0-24h while…
- Trial name
- NCT02487498
- Testing
- QVA149, Umeclidinium/vilanterol
- Where
- 53 sites in United States
- Volunteers
- 355 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Heart Failure
LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction
The study will assess the effects of 36 weeks of treatment with LCZ696 compared to valsartan on N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) in patients with chronic heart failure and preserved left-ventricular ejection…
- Trial name
- NCT00887588
- Testing
- LCZ696, Valsartan
- Where
- 81 sites in United States, Argentina and 12 more
- Volunteers
- 307 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
This is a Phase III multicenter, randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of two doses of GSK573719/GW642444 Inhalation Powder, GSK573719 Inhalation Powder via a Novel Dry…
- Trial name
- NCT01316913
- Testing
- GSK573719/GW642444 125/25, GSK573719/GW642444 62.5/25, GSK573719
- Where
- 100 sites in United States, Argentina and 8 more
- Volunteers
- 872 people
- Sponsor
- GlaxoSmithKline